Clinical trials: 2019-nCoV
Coronavirus Disease 2019 (Covid19), Hematopoietic Neoplasms
Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo)
The present study is a prospective phase IV study. All participants will receive the anti-Coronavirus Disease 2019 (COVID-19) Vaccine (messenger Ribonucleic acid-based vaccine, BNT162b2 or Comirnaty®, commercialized by…
- Trial name
- NCT04951323
- Testing
- anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)
- Where
- Belgium
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Liege
COVID-19
Coronavirus Disease 2019 (COVID-19) During Pregnancy: Prevalence of Seroconversion, Effect on Maternal and Perinatal Outcomes and Risk of Vertical Transmission (COVID-MAP)
The objectives of this proposal are to: 1) determine the rate of SARS-CoV-2 seroconversion in unselected pregnant women in Hong Kong; 2) determine the rate of SARS-CoV-2 infection in women presenting with miscarriage and…
- Trial name
- NCT04465474
- Testing
- Non Intervention
- Where
- 10 sites in China, Hong Kong and 1 more
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
SARS-CoV-2, Influenza, Human
Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)
The purpose of this clinical trial is to evaluate the safety, tolerability and efficacy of two doses (dose A and dose B) of Standardized Conditioned Medium Obtained by Coculture of M2-macrophages and fat-derived Mesenchymal…
- Conditions
- SARS-CoV-2, Influenza, Human, Respiratory Syncytial Virus Infections, Respiratory Distress Syndrome
- Trial name
- NCT06684379
- Testing
- PRS CK STORM
- Where
- 3 sites in Spain
- Volunteers
- 50 people
- Sponsor
- PEACHES BIOTECH
Coronavirus, N95
Medical Masks vs N95 Respirators for COVID-19
A randomized controlled trial in which health care workers will be randomized to either medical masks or N95 respirators when providing care to patients with COVID-19.
- Conditions
- Coronavirus, N95, Medical Mask
- Trial name
- NCT04296643
- Testing
- Medical Mask, N95 respirator
- Where
- 15 sites in Canada, Egypt and 2 more
- Volunteers
- 1,009 people
- Sponsor
- McMaster University
2019-nCoV, Immunoglobulin of Cured Patients
Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients
The new coronavirus pneumonia is an acute infectious pneumonia. The pathogen is a previously unknown new coronavirus, namely 2019 new coronavirus (2019 novel coronavirus, 2019 nCoV). However, there is no specific anti-viral drug.
- Trial name
- NCT04264858
- Testing
- Immunoglobulin of cured patients, γ-Globulin
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Coronavirus Disease (COVID-19)
Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)
The purpose of the study is to assess if the study medication (molnupiravir, MK-4482) will prevent symptomatic coronavirus disease 2019 (COVID-19) in adults who live with someone with confirmed COVID-19 infection.
- Trial name
- MOVe-AHEAD (NCT04939428)
- Testing
- Molnupiravir
- Where
- 226 sites in United States, Argentina and 21 more
- Volunteers
- 2,441 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Covid19
COVID-19 Soliris Expanded Access Protocol
This protocol provides participants with COVID-19 access to Soliris.
- Trial name
- NCT04802083
- Testing
- Eculizumab
- Sponsor
- Alexion Pharmaceuticals, Inc.
Covid-19
Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma
The investigators hypothesize that use of convalescent plasma donated from individuals recovered from Coronavirus Disease 2019 (COVID-19) will help expedite recovery of individuals with active, severe COVID-19 infection.
- Trial name
- Inova-CCP (NCT04502472)
- Testing
- Convalescent plasma transfusion
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Inova Health Care Services
COVID
Egyptian Initial Experience About 2019 Novel Corona Virus: Study of 48 Patients in Alexandria-Egypt Using Chest CT
Background: Corona virus disease 2019 (COVID-19) is a highly infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- NCT04382469
- Where
- Egypt
- Volunteers
- 48 people
- Sponsor
- Alexandria University
COVID-19
Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019
The purpose of this study is to evaluate the efficacy and safety of favipiravir combined with tocilizumab in the treatment of corona virus disease 2019.
- Trial name
- NCT04310228
- Testing
- Favipiravir Combined With Tocilizumab, Favipiravir, Tocilizumab
- Where
- 6 sites in China
- Volunteers
- 150 people
- Sponsor
- Peking University First Hospital
COVID-19
Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.
CALAVI will investigate the safety, efficacy and pharmacokinetics of acalabrutinib together with Best Supportive Care in the treatment of COVID-19.
- Trial name
- CALAVI (NCT04346199)
- Testing
- Acalabrutinib
- Where
- 50 sites in Argentina, Brazil and 12 more
- Volunteers
- 177 people
- Sponsor
- AstraZeneca
Coronavirus Disease 2019
Clinical Trials of the Consistency and Non-inferiority Bridging Between Batches of Recombinant New Coronavirus Vaccine (CHO Cells)
Popular topic:Clinical trials of the consistency and non-inferiority bridging between batches of recombinant new coronavirus vaccine (CHO cells) Research purpose:Main purpose:1)To evaluate the interbatch consistency of…
- Trial name
- NCT05091411
- Testing
- Recombinant new coronavirus vaccine (CHO cell) group
- Where
- China
- Volunteers
- 1,680 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
COVID-19, COVID-19 (SARS-CoV-2 Infection)
Evaluation of Safety, Tolerance, and Efficacy of Allogeneic LB-DTK-COV19 in Severe Coronavirus Disease 2019 Patients
The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of allogeneic SARS-CoV-2-Specific T cells (LB-DTK-COV19) in patients with persistent clinical symptoms following a positive SARS-CoV-2 PCR test…
- Trial name
- NCT07709637
- Testing
- LB-DTK-COV19
- Where
- South Korea
- Volunteers
- 1 people
- Sponsor
- LucasBio
2019-nCoV
Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus
In the absence of 2019-ncov specific therapeutic drugs, arbidol is effective against a variety of coronaviruses in vitro pharmacodynamics.
- Trial name
- NCT04260594
- Testing
- Arbidol, basic treatment
- Where
- China
- Volunteers
- 236 people
- Sponsor
- Jieming QU
Coronavirus Disease 2019
Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE)
The study will evaluate the safety and efficacy of orally-administered M5049 in Coronavirus disease 2019 (COVID-19) pneumonia participants who are hospitalized but not on mechanical ventilation.
- Trial name
- NCT04448756
- Testing
- M5049
- Where
- 21 sites in United States, Brazil and 1 more
- Volunteers
- 149 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Coronavirus Infections, Pneumonia, Viral
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)
The Severe Acute Respiratory Syndrome COronaVirus 2 (SARS-CoV2) is a new and recognized infectious disease of the respiratory tract.
- Trial name
- NCT04321278
- Testing
- Hydroxychloroquine + azithromycin, Hydroxychloroquine
- Where
- 58 sites in Brazil
- Volunteers
- 440 people
- Sponsor
- Hospital Israelita Albert Einstein
SARS-CoV-2 Infection
Evaluation of Equine Antibody Treatment in Patients With COVID 19 Infection
This is a Prospective, Randomized, Multi-center, Open label, Phase 1/2 study to Evaluate the Safety and Efficacy of Equine COVID-19 Antiserum [F(ab')2].
- Trial name
- PROTECT (NCT04834908)
- Testing
- Equine COVID-19 Antiserum, Standard of care
- Where
- India
- Volunteers
- 7 people
- Sponsor
- Bharat Serums and Vaccines Limited
COVID-19; SARS-CoV-2; 2019 Novel Coronavirus Disease
eVusheld Assessment reaL wORld Effectiveness in DoD Health System
An AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and…
- Trial name
- VALOR DoD (NCT05569408)
- Testing
- EVUSHELD
- Where
- United States
- Volunteers
- 4,724 people
- Sponsor
- AstraZeneca
COVID-19 Vaccine
ARVAC - A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine
The objective of this clinical trial is to test a new vaccine against SARS-CoV-2 (ARVAC-CG) in healthy adult volunteers, previously vaccinated against the SARS-CoV-2 virus.
- Trial name
- NCT05656508
- Testing
- ARVAC-CG vaccine (recombinant protein vaccine against SARS-CoV-2)
- Where
- Argentina
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Laboratorio Pablo Cassara S.R.L.
Coronavirus Disease 2019
Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine
Popular topic：Clinical study of recombinant Novel Coronavirus vaccine (CHO cell) combined with influenza vaccine. Research purpose:Main purpose:To evaluate the immunogenicity of recombinant Novel Coronavirus vaccine (CHO cells)…
- Trial name
- NCT05107375
- Testing
- Tetravalent influenza virus lysis vaccine, Recombinant new coronavirus vaccine (CHO cell) group
- Where
- China
- Volunteers
- 299 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.